Research programme: cancer therapeutics - Immunome

Drug Profile

Research programme: cancer therapeutics - Immunome

Alternative Names: IMM 002; IMM 003; IMM 005; IMM 009; IMM 010; IMM 039

Latest Information Update: 05 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunome
  • Class CAR-T cell therapies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer
  • Research Colorectal cancer; Solid tumours
  • Discontinued Unspecified

Most Recent Events

  • 30 Dec 2015 Immunome and the unknown biotechnology company enter into a collaboration agreement to identify and validate targets for Cancer therapeutics
  • 21 Dec 2015 Discontinued for Undefined indication in USA (Parenteral)
  • 21 Dec 2015 Early research in Colorectal cancer and Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top